一个单剂量鼻内组合的panebolavirus疫苗
Delphine C Malherbe1,2, J Brian Kimble1,2, Caroline Atyeo3
1Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
The Journal of infectious diseases
|July 20, 2023
概括
一种新的三价疫苗结合了埃博拉 (EBOV),苏丹 (SUDV) 和邦迪布吉奥 (BDBV) 病毒,通过鼻内注射,成功地保护动物免受致命的病毒挑战.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 埃博拉病毒 (EBOV,SUDV,BDBV) 导致严重的出血性疾病,死亡率高.
- 单价疫苗缺乏对这些重叠的特有病毒的交叉保护,因此需要泛埃博拉病毒疫苗.
- 人类类型3型型流感病毒 (HPIV3) 作为一个有希望的疫苗载体,用于无针的分娩和粘膜免疫.
研究的目的:
- 开发一种针对EBOV,SUDV和BDBV的组合疫苗.
- 为了评估第二代HPIV3载体泛埃博拉病毒疫苗的疗效.
主要方法:
- 第二代HPIV3疫苗结构是通过去除病毒包膜基因 (F和HN) 来设计的,以最大限度地降低抗载体免疫力.
- 创造了一种表达埃博拉病毒包膜糖蛋白的三价组合疫苗.
- 几内亚猪和被鼻腔内接种了疫苗.
主要成果:
- 内鼻接种引发了强大的幽默反应,包括结合和中和抗体和Fc介导的效应因子功能,对所有三个埃博拉病毒.
- 这种三价疫苗对致命的EBOV,SUDV和BDBV病毒具有完全的保护作用.
- 组合疫苗引起的保护与单价疫苗相美.
结论:
- 用HPIV3载体三价疫苗进行单次鼻内接种,可以有效地预防多种埃博拉病毒.
- 这种组合疫苗对于泛埃博拉病毒免疫战略具有显著价值.
更多相关视频
06:32Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
10.7K
10:39Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
12.7K
相关概念视频
01:26Pulmonary Tuberculosis IV
165
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
165
01:28Pneumonia IV: Management
359
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
359